Described herein are compositions and methods for bioluminescent analyte detection. In some embodiments, a recombinant bioluminescent polypeptide sensor is disclosed comprising a luminescent signaling domain, an analyte binding domain, and one or more peptide linkers, wherein the luminescent signaling domain is oriented in relation to the analyte binding domain such that binding of an analyte to the analyte binding domain induces a conformational change in the luminescent signaling domain to generate a luminescent signal.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.